rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AKTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform
      Nov 12Yahoo FinanceAKTX
      Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
      Nov 11Yahoo FinanceAKTX
      Akari Therapeutics shareholders approve increase in shares for 2023 equity plan
      Oct 30Investing.comAKTX
      Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
      Oct 30Yahoo FinanceAKTX
      Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
      Oct 15Yahoo FinanceAKTX
      Akari Therapeutics names Vatnak Vat-Ho as chief business officer
      Oct 13Investing.comAKTX
      Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
      Oct 13Yahoo FinanceAKTX
      Analysts’ Top Healthcare Picks: Akari Therapeutics (AKTX), Corcept Therapeutics (CORT)

      Detailed price information for Viemed Healthcare Inc (VMD-Q) from The Globe and Mail including charting and trades.

      Oct 2The Globe and MailAKTXCORT
      Akari Therapeutics increases CEO compensation and grants new equity awards
      Oct 1Investing.comAKTX
      Akari Therapeutics files patent for cancer payload technology
      Oct 1Investing.comAKTX
      Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers

      Patent filing covers PH1 payload’s unique ability to disrupt multiple cancer-driving pathways in addition to its overall cytotoxic mechanism Expands intellectual property portfolio supporting Akari’s novel payload and ADC platform TAMPA, Fla. and LONDON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing disrupting payload, today announced the filing of PCT/US2026/45955,

      Oct 1Yahoo FinanceAKTX
      Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums

      Company invited to present alongside global pharmaceutical, biotechnology and industry leaders at five high-profile U.S. and China conferences in September CEO Abizer Gaslightwala to deliver keynote and featured presentations on next-generation ADC payload innovation and partnerships/collaborations TAMPA, Fla. and LONDON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing

      Sep 8Yahoo FinanceAKTX
      Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference

      Video webcast now available here TAMPA, Fla. and LONDON, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that it participated in the Virtual Investor "Why Now" on-demand conference. During the webcast, Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, presented the Company's investment thesis, highlighti

      Aug 27Yahoo FinanceAKTX

      This is the newest page. Registered accounts read further back.